Biogen Inc (NASDAQ:BIIB) — Market Cap & Net Worth
Market Cap & Net Worth: Biogen Inc (BIIB)
Biogen Inc (NASDAQ:BIIB) has a market capitalization of $31.14 Billion ($31.14 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #880 globally and #385 in its home market, demonstrating a -2.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biogen Inc's stock price $216.01 by its total outstanding shares 147753998 (147.75 Million). Also see BIIB total asset value for a full breakdown of the balance sheet.
Biogen Inc Market Cap History: 2015 to 2026
Biogen Inc's market capitalization history from 2015 to 2026. Data shows change from $41.69 Billion to $31.92 Billion (-1.38% CAGR). Also see Biogen Inc (BIIB) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Biogen Inc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 2.95% | #10 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 2.68% | #7 of 39 |
|
S&P 500 Index
GSPC
|
$62.72 Trillion | 0.04% | #280 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 1.17% | #14 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.07% | #114 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 1.66% | #10 of 263 |
|
Nasdaq 100
NDX
|
$35.03 Trillion | 0.09% | #83 of 101 |
Weight: Biogen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biogen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biogen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Biogen Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.65x
Biogen Inc's market cap is 2.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.10x
Biogen Inc's market cap is 20.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $38.59 Billion | $11.45 Billion | $3.70 Billion | 3.37x | 10.42x |
| 2017 | $47.07 Billion | $12.27 Billion | $2.54 Billion | 3.83x | 18.54x |
| 2018 | $44.46 Billion | $13.45 Billion | $4.43 Billion | 3.31x | 10.04x |
| 2019 | $43.84 Billion | $14.38 Billion | $5.89 Billion | 3.05x | 7.45x |
| 2020 | $36.18 Billion | $13.44 Billion | $4.00 Billion | 2.69x | 9.04x |
| 2021 | $35.45 Billion | $10.98 Billion | $1.56 Billion | 3.23x | 22.78x |
| 2022 | $40.92 Billion | $10.17 Billion | $3.05 Billion | 4.02x | 13.43x |
| 2023 | $38.23 Billion | $9.84 Billion | $1.16 Billion | 3.89x | 32.93x |
| 2024 | $22.59 Billion | $9.68 Billion | $1.63 Billion | 2.34x | 13.84x |
| 2025 | $26.00 Billion | $9.81 Billion | $1.29 Billion | 2.65x | 20.10x |
Competitor Companies of BIIB by Market Capitalization
Companies near Biogen Inc in the global market cap rankings as of September 17, 2026. Review BIIB tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biogen Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $1.01 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #44 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $1.01 Trillion | $1137.82 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $267.28 |
| #44 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $262.51 |
Biogen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Biogen Inc's market cap moved from $41.69 Billion to $ 31.92 Billion, with a yearly change of -1.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $31.92 Billion | +22.74% |
| 2025 | $26.00 Billion | +15.09% |
| 2024 | $22.59 Billion | -40.91% |
| 2023 | $38.23 Billion | -6.55% |
| 2022 | $40.92 Billion | +15.42% |
| 2021 | $35.45 Billion | -2.02% |
| 2020 | $36.18 Billion | -17.48% |
| 2019 | $43.84 Billion | -1.39% |
| 2018 | $44.46 Billion | -5.54% |
| 2017 | $47.07 Billion | +21.96% |
| 2016 | $38.59 Billion | -7.43% |
| 2015 | $41.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Biogen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.14 Billion USD |
| MoneyControl | $31.14 Billion USD |
| MarketWatch | $31.14 Billion USD |
| marketcap.company | $31.14 Billion USD |
| Reuters | $31.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more